Quantamatrix Inc. (317690)
Market Closed
11 Aug, 06:30
KRX SM KRX SM Primary ₩
2,885. 00
+190
+7.0501%
₩
73.3B Market Cap
- P/E Ratio
- Div Yield
1.18M Volume
- Eps
₩ 2,695
Previous Close Want to track 317690 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
317690 closed today higher at ₩2,885, an increase of 7.0501% from yesterday's close, completing a monthly increase of 9.4877% or ₩250. Over the past 12 months, 317690 stock lost -39.7074%.
317690 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Quantamatrix Inc. (317690) FAQ
What is the stock price today?
The current price is ₩2,885.00.
On which exchange is it traded?
Quantamatrix Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 317690.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 73.3B.
Has Quantamatrix Inc. ever had a stock split?
No, there has never been a stock split.
Quantamatrix Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Sung Hoon Kwon CEO | KRX SM Exchange | - ISIN |
| KR Country | 92 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
QuantaMatrix Inc. is a South Korea-based in-vitro diagnostics company established in 2010. With a focus on developing rapid and direct diagnostic tests, the company is at the forefront of battling diseases such as sepsis, tuberculosis, Alzheimer's disease, and cardiovascular diseases by providing early and accurate diagnostic solutions. Located in Seoul, South Korea, QuantaMatrix is committed to innovation in the medical diagnostics field, aiming to improve patient outcomes through its specialized products.
Products and Services
- dRAST - This product represents a groundbreaking approach to combating sepsis, offering direct and rapid antimicrobial susceptibility testing from positive blood cultures. It delivers Minimum Inhibitory Concentration (MIC)-based phenotypic results, which are crucial for effective treatment decisions.
- QDST - Aimed at tackling tuberculosis, the QDST system stands out by enabling rapid phenotypic drug susceptibility testing. This greatly aids in the quick and accurate prescription of treatment regimens for patients afflicted with TB.
- QPLEX Alz Plus Assay - Focusing on neurodegenerative diseases, the QPLEX Alz Plus Assay is a cutting-edge early diagnosis kit for Alzheimer’s disease. It provides a significant advantage in the early detection and management of this debilitating condition.
- Quanti9 and QuantiGal - These prognostic prediction kits are designed for cardiovascular diseases, offering a new method for assessing the risk levels associated with such conditions. Their innovative approach to prognosis helps in the strategic planning of preventative measures and treatments.
Contact Information
Address: Suite 217 Bldg. 104
Phone: 82 70 7578 1738
Website: https://www.quantamatrix.com
